CIRM Funded Clinical Trials

Autologous BCMA CAR-T Cells for the Treatment of Relapsed Refractory Light Chain Amyloidosis

Disease Area:
Blood Disorders
Investigator:
Institution:
CIRM Grant:
CLIN2-15901 (Pre-Active)
Award Value:
$7,999,467.00
Trial Sponsor:
Nexcella, Inc.
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov